GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Fidaxomicin (Dificid)

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug5 sources available - open source summaries, references and comparisons

Dificid / Fidaxomicin

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (5)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Dificid - product and source limitations

Applies to oral therapy for C. difficile infection. Select the age- and formulation-appropriate regimen.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Dificid - product and source limitations

Professional source

UCSF - fidaxomicin for C. difficile

Choose a product and source Dificid | Product label Dificid | GlobalRPh RX passage All evidence
Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal measure
Qualitative no-adjustment guidance.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05 (not the revision date)

Dosing / renal protocol and limits

For adult C. difficile infection, the dose is 200 mg orally every 12 hours. UCSF retains this schedule in renal dysfunction and hemodialysis. Select the CDI treatment course under the applicable infection guideline; this is not systemic antibacterial treatment.

Source revision: Revision date not stated in the reviewed page. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://idmp.ucsf.edu/content/fidaxomicin

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v7.4

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Dificid - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 22, posted Oct 15, 2026

Renal measure: Renal impairment categories as defined by the cited product label

Read this dated source finding
Rxlist

Dificid - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
See all retained evidence sources
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Dificid - labeled renal guidance

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Fidaxomicin (Dificid), oral tablet

Renal method: Renal impairment categories as defined by the cited product label
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
Handbook

Renal Drug Handbook, 5th edition - Fidaxomicin

Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Retrieved: 2026-09-05

Read local renal resultOpen this source quick answer

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Dificid - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Dificid - product and source limitations

Applies to oral therapy for C. difficile infection. Select the age- and formulation-appropriate regimen.

How to use this: Apply only to the stated formulation, indication and renal population.

Dificid - labeled renal guidanceDificid - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Handbook source

Renal Drug Handbook, 5th edition - Fidaxomicin

Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.

Historical renal / replacement-therapy guidanceRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeDIFICID - adult oral C. difficile regimenDificid - labeled renal guidanceDificid - selected RX renal passageUCSF - fidaxomicin for C. difficileRenal Drug Handbook, 5th edition - Fidaxomicin
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd966338-c820-4270-b704-09ef75fa3ceb

Product and population scope

Adult Fidaxomicin (Dificid). Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.

SCOPE-fidaxomicin · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

DIFICID - adult oral C. difficile regimen

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. product labeling · Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: No renal-function dose bands specified for this summary.
Source date: DailyMed updated 2024-10-16.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Adult C. difficile-associated diarrhea: 200 mg orally twice daily for 10 days, with or without food. No dose adjustment is recommended based on renal function, including the severe-impairment category studied (CrCl <=30 mL/min). The label does not provide a distinct dialysis replacement dose.

This is an oral intestinal-infection regimen, not treatment of systemic infection. Do not substitute the pediatric suspension volume table without confirming age, weight and concentration.

RDM30-074-fidaxomicin-1 · Source locator: DIFICID - adult oral C. difficile regimen; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd966338-c820-4270-b704-09ef75fa3ceb
Retrieved
2026-09-05
DailyMed Set ID
dd966338-c820-4270-b704-09ef75fa3ceb
Renal-function method
No renal-function dose bands specified for this summary.
Source date/version
DailyMed updated 2024-10-16.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
60e1804dd4a81741e3cb45c08921a6dcbc8d61b0b0f4b6a61f0c1cd34f24dc45
Official

Dificid - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Fidaxomicin (Dificid), oral tablet

Renal method: Renal impairment categories as defined by the cited product label
Source date: DailyMed SPL version 22, posted Oct 15, 2026
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: Prescribing information, renal precautions and clinical pharmacology

Oral fidaxomicin requires no adjustment for kidney function. Applies to oral therapy for C. difficile infection. Select the age- and formulation-appropriate regimen.

RDM74-dificid-official-1 · Source locator: Renal guidance: Prescribing information, renal precautions and clinical pharmacology

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd966338-c820-4270-b704-09ef75fa3ceb
Retrieved
2026-11-07
Renal-function method
Renal impairment categories as defined by the cited product label
Source date/version
DailyMed SPL version 22, posted Oct 15, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
565b0e790e2cf9d3e38721e3237774e2433f654cf75ddbc3421e6149f3e7d802
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Dificid - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Fidaxomicin (Dificid), oral tablet

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror reports no renal dose modification.

RDM74-dificid-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/dificid-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
9df460afd2562776fdd3124c879dd66952ae68796885d07bcd4ef816822156b4
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, 5th edition - Fidaxomicin

Open / share this exact local source

UK Renal Pharmacy Group / CRC Press · Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Source date: 5th edition; 2019 copyright; historical reference
Retrieved: 2026-09-05

Historical handbook cross-check; not a current U.S. protocol

Historical renal / replacement-therapy guidance

The 20-50, 10-20 and <10 mL/min bands retain the usual indication-specific dose. The <10 band adds caution. The adult C. difficile regimen is 200 mg twice daily for 10 days. PD, HD, high-flux and continuous therapy retain usual dosing; removal is considered unlikely. The book notes older UK caution below 30 because of limited data, while its renal dose recommendation draws on U.S. information.

HB30-fidaxomicin-1 · Source locator: Printed page 427: renal impairment, RRT and other information

Source-specific limits

Separate source recommendation, not proof of agreement or contemporary clinical validation. Dialysis predictions are retained with their original certainty.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
5th edition, printed p. 427; uploaded PDF p. 446
Renal-function method
Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Source date/version
5th edition; 2019 copyright; historical reference
U.S. product identity basis
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd966338-c820-4270-b704-09ef75fa3ceb
Hash meaning
Local paraphrase; original book not redistributed
Local summary SHA-256
33a9ef416663fd83a8ac7aa9f9b7ec0408af7f9d1f1311397974bc621d6bb072
Separate professional-source layer

University and professional protocols

Professional

UCSF - fidaxomicin for C. difficile

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: Qualitative no-adjustment guidance.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

For adult C. difficile infection, the dose is 200 mg orally every 12 hours. UCSF retains this schedule in renal dysfunction and hemodialysis. Select the CDI treatment course under the applicable infection guideline; this is not systemic antibacterial treatment.

RDM30-038-fidaxomicin-1 · Source locator: UCSF - fidaxomicin for C. difficile; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/fidaxomicin
Retrieved
2026-09-05
Renal-function method
Qualitative no-adjustment guidance.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
02e296a3639e6220447c3ccc7c88794835e67fd882ff184b2156da46300070cb

Provenance and preservation

Additional summaries stored on this page: 2 official-label, 1 RX List, 1 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd966338-c820-4270-b704-09ef75fa3ceb
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
b896e9734d5499c0e4bcade616f9f8e8e9b0242f6b71f76b0ad9af334ec4ea80
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top